www.rmpd.org.uk

You are here: Home > Innovation > Technology Transferred > Durham Erythema Test Device

Durham Erythema Test Device

Psoriasis is a skin disease that affects 2% of the population. One of the common ways of treating this condition is to expose patients to ultraviolet-B (UVB) radiation. Measuring the sensitivity of patients' skin to UV radiation before they embark on a course of UVB treatment for their skin disease can make the treatment more effective. This measurement, or phototest, involves exposing small areas of skin to increasing doses of UVB radiation and noting the smallest dose (called the minimal erythema dose or MED) that results in a slight redness of the test site 24 hours after exposure.

The Durham UVB Erythema Test Device was designed by physicists Phil Saunders and Professor Brian Diffey to make phototesting a simple, quick and reproducible exercise that can be carried out with the minimum of training. Just a single exposure lasting around 30 seconds results in a series of 10 doses of UVB covering an 8-fold dose range.

A licensing agreement to manufacture this device has been negotiated with Hybec Limited, a Miyakawa Corporation Company of Japan with effect from August 2002.

Independent audit

Researchers have recently proven the worth of the Durham Erythema Test Device. A British Journal of Dermatology paper† states that. "A recent comparison between the 'Durham' minimal erythema dose (MED) testing device and the older method found the Durham MED tester to be a convenient, safe and effective tool for determining patient MED values prior to narrow band UVB phototherapy." It goes on to state that. "These results show that the Durham MED tester gives very reproducible results. ... We conclude that the Durham MED test method is highly reproducible when used under carefully controlled lighting, using experienced observers."

† Otman SG, Edwards C, Wyness K, Anstey AV. British Photodermatology Group: Summaries of Papers PD-7. Reproducibility of a semi-automated method of minimal erythema dose testing. British Journal of Dermatology (2005) 153 (Suppl. 1): 92-98.

For further details contact:

Hybec Limited
Unit 9 Barrington Industrial Estate
Leycroft Road
Leicester LE4 1ET

Telephone: 0116-234-2929
Facsimile: 0116-235-8810
E-mail: hls@hybec.com
Web: www.hybec.com

Top of page

W3C XHTML 1.0 logo
W3C CSS logo
Triple-A conformance icon, W3C-WAI Web Content Accessibility Guidelines 1.0
Internet Content Rating Association logo

Regional Medical Physics Department, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK.
Tel: +44 (0)191-233-6161 E-mail: webmaster@rmpd.org.uk Web: http://www.rmpd.org.uk
By using this site you agree to our Terms and Conditions of Use. Please read our legal page.
Regional Medical Physics Department, a Clinical Directorate of the Newcastle upon Tyne Hospitals NHS Foundation Trust.
Copyright ©1999-2008 All Rights Reserved. Revised 7 November, 2008.

This Web Site

Accessibility | Feedback | Help | Links | Site Map | What's New |

Our Organisation

FAQs | Find Us | News & Events | Services | Work For Us |

Our Research

Abstracts | Innovation | Publications | What We Do |

Quick Site Search

Advanced search